Catalent

Catalent, Inc. is a global leader in pharmaceutical development, manufacturing, and supply chain solutions, based in Somerset, New Jersey. As a subsidiary of Novo Holdings A/S since 2024, the company operates 53 facilities across four continents and employs approximately 16,900 people. Catalent plays a vital role in the pharmaceutical industry, contributing to over half of FDA-approved products in the last decade and producing 70 billion doses annually for around 8,000 products. Founded in 2007, Catalent specializes in drug delivery technologies, development and manufacturing, clinical solutions, and biologics and gene therapy. Its offerings include softgel capsules, orally disintegrating tablets, and advanced manufacturing capabilities for monoclonal antibodies and vaccines. The company partners with leading pharmaceutical and biotech firms, providing essential services for rapid scale-up, particularly during public health crises. In 2024, Catalent reported $4.38 billion in revenue, reflecting its extensive operational scale and commitment to innovation in the pharmaceutical sector.